Abstract
Background Combining poly (ADP-ribose) polymerase (PARP) with phosphatidylinositol-3-kinase (PI3K) pathway inhibitors is supported by strong preclinical rationale. We sought to assess safety and determine a recommended phase 2 dose (RP2D) for PARP inhibitor olaparib combined with the AKT inhibitor, capivasertib, and evaluate molecular markers of response and resistance.
Methods As part of a larger phase 1b trial, we performed a safety lead in of olaparib and capivasertib followed by expansion (n=24) in endometrial, triple negative breast, ovarian, fallopian tube, or peritoneal cancer. Olaparib 300mg orally twice daily and capivasertib orally twice daily on a four day on three day off schedule was evaluated. Two dose levels (DL) were planned: capivasertib 400mg (DL1); capivasertib 320mg (DL-1). Patients underwent biopsies at baseline and after 28 days.
Findings 38 patients were enrolled. 7 (18%) patients had known germline BRCA1/2 mutations. The first two patients on DL1 experienced dose limiting toxicities (DLTs) of diarrhea and vomiting in absence of maximum supportive care. No DLTs were observed on DL-1 (n=6), therefore, DL1 was re-explored (n=6) with no DLTs, confirming this as RP2D. Most common treatment-related grade 3 or 4 adverse events were anemia (23.7%) and leukopenia (10.5%).
Of 32 subjects evaluable for response, 6 (19%) had partial response (PR) with a PR rate of 44.4% in endometrial cancer. Seven (22%) additional patients had stable disease greater than 4 months. Tumor analysis demonstrated strong correlation between response and immune activity, as well as alterations in cell cycle and DNA damage response genes. Therapy resistance was associated with receptor tyrosine kinase (RTK) and RAS-MAPK pathway activity, as well as metabolism and epigenetics.
Interpretation The combination of olaparib and capivasertib is well tolerated and demonstrates evidence of durable activity in women’s cancers, with particularly promising response in endometrial cancer. Importantly, tumor samples acquired pre and on-therapy can help predict patient benefit.
Funding AstraZeneca, MDACC Moonshots Program, MDACC Support Grant CA016672 NCI SPOREs in Ovarian (CA217685) and Uterine (CA098258) Cancer and a kind gift from the Miriam and Sheldon Medical Research Foundation. AZD5363 was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).
Competing Interest Statement
SNW reports personal fees for consulting from Agenus, AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, Eisai, Zentalis and research funding to institution from ArQule, AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. JKL notes research funding to institution from Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, AstraZeneca, Medimmune and Zenith. PTS notes personal fees for consulting from Amgen and research funding to institution from Novartis and Incyte. MF notes personal fees for consulting from Stryker and research support to institution from AstraZeneca and GSK. AJ notes personal fees for consulting from Gerson and Lehrman Group, Guidepoint, Iovance, Nuprobe, Simcere, Pact Pharma, Roche/Genentech, Eisai, Agenus, Macrogenics, Instil Bio; research funding to institution from AstraZeneca, BMS, Aravive, Iovance, Pfizer, Immantic USA, Eli Lilly, Merck, and stock options from AvengeBio. LAM notes research funding to institution from AstraZeneca. CCS notes research support from AstraZeneca. AKS notes personal fees for consulting from Kiyatec, Merck, AstraZeneca, and stock in Bio-Path. RLC notes personal fees for consulting from Abbvie, AstraZeneca, Clovis, Immunogen, GSK, Array, Genmab, Novocure, Agenus, Gradalis, Epsilogen, Deciphera, Genentech/Roche, Aravive, OncXerna, Alkermes and research support to institution from AstraZeneca, Abbvie, Clovis, Roche/Genentech, Novartis, Janssen, Merck, Genmab, and Immunogen. GBM notes personal fees for consulting from Abbvie, Amphista, AstraZeneca, Chrysallis Biotechnology, GSK, ELlipses Pharma, ImmunoMET, Ionis, Lilly, Medacorp, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine, Zentalis Pharmaceuticals; stock options from Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, Turbine; Licensed Technology of HRD assay to Myriad Genetics, and DSP patents with Nanostring. All other authors note no conflicts of interest.
Clinical Trial
NCT02208375
Funding Statement
AstraZeneca, MDACC Moonshots Program, MDACC Support Grant CA016672 NCI SPOREs in Ovarian (CA217685) and Uterine (CA098258) Cancer and a kind gift from the Miriam and Sheldon Medical Research Foundation. AZD5363 was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted at The University of Texas MD Anderson Cancer Center (MDACC) under an IRB-approved protocol. The trial was registered at clinicaltrials.gov as NCT02208375.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript will be made available upon reasonable request.
